ArticleHaematologica2019
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Randomized Phase II Study of Brentuximab-Vedotin With High-Dose Chemotherapy in CD30 Positive Lymphoma.Hematological oncology · 2025Trial
- Trial
- Trial
- Trial
- Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.Blood advances · 2020Trial
- Emerging therapeutic strategies for CD30-positive lymphomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Pediatric Autologous Hematopoietic Stem Cell Transplantation: Safety, Efficacy, and Patient Outcomes. Literature Review.Pediatric health, medicine and therapeutics · 2023Review
- Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma.Frontiers in immunology · 2023Article
- Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation-A Phase I Study.Journal of clinical medicine · 2022Article
- Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.Hematological oncology · 2022Article
- Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.Leukemia · 2021Article
- Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma.Bone marrow transplantation · 2020Article
- Antibody-Drug Conjugates: The Last Decade.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Treatment of very high-risk classical Hodgkin Lymphoma: cases' selection from real life and critical review of the literature.Acta bio-medica : Atenei Parmensis · 2020Review
- Review
- Salvage Therapy for Hodgkin's Lymphoma: A Review of Current Regimens and Outcomes.Journal of blood medicine · 2020Review
- Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.Therapeutic advances in hematology · 2020Review
- Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma.OncoTargets and therapy · 2020Review
- Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.Advances in therapy · 2019Review
- Production and Evaluation of an Avian IgY Immunotoxin against CD133+ for Treatment of Carcinogenic Stem Cells in Malignant Glioma: IgY Immunotoxin for the Treatment of Glioblastoma.Journal of oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.